RxDoctor Payments Data

Simcha Weissman, DO

Internal Medicine · North Bergen, NJNPI 1457810798

Payments from drug & device makers

$560in general payments, 2019–2025

Across 15 payments — averaging $37.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$245
  • Inari Medical, Inc.$133
  • GSK$78
  • Pfizer$48
  • Novo Nordisk$28
  • Exact Sciences$15
  • plus $14 from 1 others

What the payments were for

  • Food & beverage$560100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$560 in reported general payments places this provider in the 55th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$54,004
Medicare patients
118
Services billed
550

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate22$51,115
JardianceEmpagliflozin114$28,766
EliquisApixaban97$18,130
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$9,820
VascepaIcosapent Ethyl33$9,729
FarxigaDapagliflozin Propanediol32$9,067
AbrysvoRsv Vacc, Pref A And Pref B/Pf19$6,510
RexultiBrexpiprazole20$5,823
TradjentaLinagliptin24$4,511
ShingrixVaricella-Zoster Ge/As01b/Pf15$3,520
Diclofenac Sodium17$3,192
Pantoprazole Sodium252$1,758
Atorvastatin Calcium292$1,698
Fiasp FlextouchInsulin Aspart (Niacinamide)12$1,551
Megestrol Acetate18$1,480

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$245$33,277138 claims
PfizerEliquis, Abrysvo$48$24,640116 claims
GSKTrelegy Ellipta, Shingrix$78$13,34030 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 4,032 internal medicine providers in New Jersey.

Other internal medicine in North Bergen

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →